nodes	percent_of_prediction	percent_of_DWPC	metapath
Hydralazine—CYP3A4—breast cancer	0.248	1	CbGaD
Hydralazine—CYP3A4—Exemestane—breast cancer	0.0518	0.133	CbGbCtD
Hydralazine—CYP3A4—Letrozole—breast cancer	0.0441	0.113	CbGbCtD
Hydralazine—CYP3A4—Anastrozole—breast cancer	0.0393	0.101	CbGbCtD
Hydralazine—CYP3A4—Toremifene—breast cancer	0.0359	0.0921	CbGbCtD
Hydralazine—CYP3A4—Fulvestrant—breast cancer	0.0334	0.0856	CbGbCtD
Hydralazine—CYP3A4—Thiotepa—breast cancer	0.0298	0.0763	CbGbCtD
Hydralazine—CYP3A4—Ixabepilone—breast cancer	0.0272	0.0698	CbGbCtD
Hydralazine—CYP3A4—Lapatinib—breast cancer	0.0262	0.0672	CbGbCtD
Hydralazine—CYP3A4—Raloxifene—breast cancer	0.0199	0.0509	CbGbCtD
Hydralazine—CYP3A4—Vinorelbine—breast cancer	0.0145	0.0373	CbGbCtD
Hydralazine—CYP3A4—Tamoxifen—breast cancer	0.0131	0.0336	CbGbCtD
Hydralazine—CYP3A4—Mitoxantrone—breast cancer	0.0128	0.0328	CbGbCtD
Hydralazine—CYP3A4—Paclitaxel—breast cancer	0.0102	0.0262	CbGbCtD
Hydralazine—CYP3A4—Irinotecan—breast cancer	0.0101	0.0258	CbGbCtD
Hydralazine—CYP3A4—Vinblastine—breast cancer	0.00896	0.023	CbGbCtD
Hydralazine—CYP3A4—Docetaxel—breast cancer	0.00738	0.0189	CbGbCtD
Hydralazine—AOC3—mammary gland—breast cancer	0.0058	0.0715	CbGeAlD
Hydralazine—CYP3A4—Doxorubicin—breast cancer	0.0055	0.0141	CbGbCtD
Hydralazine—AOC3—nipple—breast cancer	0.0048	0.0591	CbGeAlD
Hydralazine—RYR2—uterus—breast cancer	0.00444	0.0546	CbGeAlD
Hydralazine—RYR2—pituitary gland—breast cancer	0.00436	0.0536	CbGeAlD
Hydralazine—RYR2—female reproductive system—breast cancer	0.00399	0.0491	CbGeAlD
Hydralazine—RYR2—adrenal gland—breast cancer	0.00389	0.0479	CbGeAlD
Hydralazine—P4HA1—nipple—breast cancer	0.00384	0.0472	CbGeAlD
Hydralazine—RYR2—female gonad—breast cancer	0.00363	0.0447	CbGeAlD
Hydralazine—RYR2—endocrine gland—breast cancer	0.00338	0.0416	CbGeAlD
Hydralazine—AOC3—endometrium—breast cancer	0.0029	0.0357	CbGeAlD
Hydralazine—AOC3—uterus—breast cancer	0.00267	0.0329	CbGeAlD
Hydralazine—AOC3—pituitary gland—breast cancer	0.00262	0.0323	CbGeAlD
Hydralazine—AOC3—adipose tissue—breast cancer	0.00261	0.0322	CbGeAlD
Hydralazine—AOC3—female reproductive system—breast cancer	0.0024	0.0296	CbGeAlD
Hydralazine—AOC3—adrenal gland—breast cancer	0.00234	0.0288	CbGeAlD
Hydralazine—P4HA1—endometrium—breast cancer	0.00232	0.0285	CbGeAlD
Hydralazine—AOC3—bone marrow—breast cancer	0.00227	0.0279	CbGeAlD
Hydralazine—AOC3—female gonad—breast cancer	0.00218	0.0269	CbGeAlD
Hydralazine—P4HA1—uterus—breast cancer	0.00214	0.0263	CbGeAlD
Hydralazine—P4HA1—pituitary gland—breast cancer	0.0021	0.0258	CbGeAlD
Hydralazine—P4HA1—adipose tissue—breast cancer	0.00209	0.0257	CbGeAlD
Hydralazine—AOC3—endocrine gland—breast cancer	0.00203	0.025	CbGeAlD
Hydralazine—P4HA1—female reproductive system—breast cancer	0.00192	0.0236	CbGeAlD
Hydralazine—P4HA1—adrenal gland—breast cancer	0.00187	0.0231	CbGeAlD
Hydralazine—P4HA1—bone marrow—breast cancer	0.00181	0.0223	CbGeAlD
Hydralazine—P4HA1—female gonad—breast cancer	0.00175	0.0215	CbGeAlD
Hydralazine—P4HA1—endocrine gland—breast cancer	0.00162	0.02	CbGeAlD
Hydralazine—AOC3—lymph node—breast cancer	0.0014	0.0173	CbGeAlD
Hydralazine—RYR2—SIDS Susceptibility Pathways—THRB—breast cancer	0.00126	0.0236	CbGpPWpGaD
Hydralazine—RYR2—Ion channel transport—ATP7B—breast cancer	0.00117	0.022	CbGpPWpGaD
Hydralazine—P4HA1—lymph node—breast cancer	0.00112	0.0138	CbGeAlD
Hydralazine—RYR2—Arrhythmogenic Right Ventricular Cardiomyopathy—TCF7L2—breast cancer	0.00109	0.0204	CbGpPWpGaD
Hydralazine—RYR2—SIDS Susceptibility Pathways—PPARGC1B—breast cancer	0.00109	0.0204	CbGpPWpGaD
Hydralazine—RYR2—Calcium Regulation in the Cardiac Cell—RGS2—breast cancer	0.001	0.0188	CbGpPWpGaD
Hydralazine—RYR2—Myometrial Relaxation and Contraction Pathways—RGS2—breast cancer	0.000971	0.0182	CbGpPWpGaD
Hydralazine—RYR2—Myometrial Relaxation and Contraction Pathways—LPAR1—breast cancer	0.00093	0.0174	CbGpPWpGaD
Hydralazine—RYR2—SIDS Susceptibility Pathways—FOXM1—breast cancer	0.000915	0.0172	CbGpPWpGaD
Hydralazine—RYR2—Myometrial Relaxation and Contraction Pathways—PDE4D—breast cancer	0.000878	0.0165	CbGpPWpGaD
Hydralazine—CYP3A4—Codeine and Morphine Metabolism—SLCO1B1—breast cancer	0.000844	0.0158	CbGpPWpGaD
Hydralazine—RYR2—SIDS Susceptibility Pathways—ALDOA—breast cancer	0.000824	0.0155	CbGpPWpGaD
Hydralazine—RYR2—SIDS Susceptibility Pathways—CPT1A—breast cancer	0.000778	0.0146	CbGpPWpGaD
Hydralazine—RYR2—Transmembrane transport of small molecules—SLC28A1—breast cancer	0.000777	0.0146	CbGpPWpGaD
Hydralazine—RYR2—Myometrial Relaxation and Contraction Pathways—IGFBP3—breast cancer	0.000762	0.0143	CbGpPWpGaD
Hydralazine—RYR2—Transmembrane transport of small molecules—SLC2A10—breast cancer	0.00071	0.0133	CbGpPWpGaD
Hydralazine—RYR2—Transmembrane transport of small molecules—SLC4A7—breast cancer	0.00071	0.0133	CbGpPWpGaD
Hydralazine—RYR2—SIDS Susceptibility Pathways—GATA3—breast cancer	0.00068	0.0128	CbGpPWpGaD
Hydralazine—RYR2—Myometrial Relaxation and Contraction Pathways—CALCA—breast cancer	0.00064	0.012	CbGpPWpGaD
Hydralazine—RYR2—SIDS Susceptibility Pathways—ESR2—breast cancer	0.000611	0.0115	CbGpPWpGaD
Hydralazine—RYR2—Transmembrane transport of small molecules—COX11—breast cancer	0.000589	0.011	CbGpPWpGaD
Hydralazine—RYR2—Transmembrane transport of small molecules—SLC39A7—breast cancer	0.000589	0.011	CbGpPWpGaD
Hydralazine—RYR2—SIDS Susceptibility Pathways—EGR1—breast cancer	0.000571	0.0107	CbGpPWpGaD
Hydralazine—RYR2—SIDS Susceptibility Pathways—AR—breast cancer	0.00054	0.0101	CbGpPWpGaD
Hydralazine—CYP3A4—Irinotecan Pathway—SLCO1B1—breast cancer	0.000539	0.0101	CbGpPWpGaD
Hydralazine—RYR2—Transmembrane transport of small molecules—SLC22A18—breast cancer	0.000538	0.0101	CbGpPWpGaD
Hydralazine—RYR2—Calcium Regulation in the Cardiac Cell—ITPR1—breast cancer	0.000524	0.00983	CbGpPWpGaD
Hydralazine—RYR2—Transmembrane transport of small molecules—SLCO1B1—breast cancer	0.000518	0.00972	CbGpPWpGaD
Hydralazine—RYR2—Transmembrane transport of small molecules—SLC2A5—breast cancer	0.000518	0.00972	CbGpPWpGaD
Hydralazine—CYP3A4—female reproductive system—breast cancer	0.000509	0.00626	CbGeAlD
Hydralazine—RYR2—Myometrial Relaxation and Contraction Pathways—ITPR1—breast cancer	0.000508	0.00953	CbGpPWpGaD
Hydralazine—RYR2—SIDS Susceptibility Pathways—HES1—breast cancer	0.000474	0.0089	CbGpPWpGaD
Hydralazine—CYP3A4—Drug Induction of Bile Acid Pathway—SLCO1B1—breast cancer	0.000462	0.00866	CbGpPWpGaD
Hydralazine—RYR2—Transmembrane transport of small molecules—SLC39A6—breast cancer	0.000446	0.00837	CbGpPWpGaD
Hydralazine—RYR2—Arrhythmogenic Right Ventricular Cardiomyopathy—CTNNB1—breast cancer	0.000432	0.00811	CbGpPWpGaD
Hydralazine—CYP3A4—endocrine gland—breast cancer	0.000431	0.0053	CbGeAlD
Hydralazine—RYR2—Stimuli-sensing channels—RAF1—breast cancer	0.000409	0.00767	CbGpPWpGaD
Hydralazine—RYR2—Transmembrane transport of small molecules—ATP7B—breast cancer	0.000408	0.00766	CbGpPWpGaD
Hydralazine—CYP3A4—Fatty Acid Omega Oxidation—ALDH1A1—breast cancer	0.000398	0.00747	CbGpPWpGaD
Hydralazine—RYR2—SIDS Susceptibility Pathways—HIF1A—breast cancer	0.000397	0.00746	CbGpPWpGaD
Hydralazine—CYP3A4—Irinotecan Pathway—ABCC1—breast cancer	0.000395	0.00741	CbGpPWpGaD
Hydralazine—RYR2—Transmembrane transport of small molecules—ABCC1—breast cancer	0.000379	0.00712	CbGpPWpGaD
Hydralazine—CYP3A4—Codeine and Morphine Metabolism—CYP2D6—breast cancer	0.000374	0.00702	CbGpPWpGaD
Hydralazine—CYP3A4—Tryptophan metabolism—ALDH3A2—breast cancer	0.00035	0.00657	CbGpPWpGaD
Hydralazine—RYR2—Myometrial Relaxation and Contraction Pathways—FOS—breast cancer	0.000336	0.0063	CbGpPWpGaD
Hydralazine—RYR2—Transmembrane transport of small molecules—TUBB3—breast cancer	0.000322	0.00605	CbGpPWpGaD
Hydralazine—CYP3A4—Liver X Receptor Pathway—FASN—breast cancer	0.000298	0.00559	CbGpPWpGaD
Hydralazine—CYP3A4—Benzo(a)pyrene metabolism—CYP1B1—breast cancer	0.000295	0.00554	CbGpPWpGaD
Hydralazine—RYR2—Myometrial Relaxation and Contraction Pathways—NOS3—breast cancer	0.000292	0.00548	CbGpPWpGaD
Hydralazine—CYP3A4—Aflatoxin B1 metabolism—GSTM1—breast cancer	0.000289	0.00542	CbGpPWpGaD
Hydralazine—CYP3A4—Estrogen metabolism—SULT1A1—breast cancer	0.000284	0.00533	CbGpPWpGaD
Hydralazine—CYP3A4—Estrogen metabolism—GSTA1—breast cancer	0.000278	0.00521	CbGpPWpGaD
Hydralazine—CYP3A4—Irinotecan Pathway—ABCG2—breast cancer	0.000274	0.00513	CbGpPWpGaD
Hydralazine—RYR2—Transmembrane transport of small molecules—SLC2A2—breast cancer	0.000268	0.00504	CbGpPWpGaD
Hydralazine—CYP3A4—Codeine and Morphine Metabolism—ABCB1—breast cancer	0.000267	0.00501	CbGpPWpGaD
Hydralazine—RYR2—Ion channel transport—RAF1—breast cancer	0.000267	0.005	CbGpPWpGaD
Hydralazine—RYR2—Transmembrane transport of small molecules—ABCG2—breast cancer	0.000263	0.00493	CbGpPWpGaD
Hydralazine—RYR2—SIDS Susceptibility Pathways—CXCL8—breast cancer	0.000258	0.00484	CbGpPWpGaD
Hydralazine—CYP3A4—Tamoxifen metabolism—SULT1A1—breast cancer	0.000251	0.00471	CbGpPWpGaD
Hydralazine—RYR2—Myometrial Relaxation and Contraction Pathways—IL1B—breast cancer	0.000249	0.00467	CbGpPWpGaD
Hydralazine—RYR2—SIDS Susceptibility Pathways—IL1B—breast cancer	0.000247	0.00464	CbGpPWpGaD
Hydralazine—RYR2—SIDS Susceptibility Pathways—CASP3—breast cancer	0.000247	0.00463	CbGpPWpGaD
Hydralazine—RYR2—Myometrial Relaxation and Contraction Pathways—JUN—breast cancer	0.000241	0.00452	CbGpPWpGaD
Hydralazine—RYR2—SIDS Susceptibility Pathways—JUN—breast cancer	0.00024	0.0045	CbGpPWpGaD
Hydralazine—RYR2—SIDS Susceptibility Pathways—CTNNB1—breast cancer	0.000238	0.00446	CbGpPWpGaD
Hydralazine—RYR2—Transmembrane transport of small molecules—TFRC—breast cancer	0.000234	0.0044	CbGpPWpGaD
Hydralazine—CYP3A4—Irinotecan Pathway—BCHE—breast cancer	0.000227	0.00425	CbGpPWpGaD
Hydralazine—RYR2—Transmembrane transport of small molecules—NCOA2—breast cancer	0.000226	0.00423	CbGpPWpGaD
Hydralazine—CYP3A4—Benzo(a)pyrene metabolism—CYP1A1—breast cancer	0.000224	0.0042	CbGpPWpGaD
Hydralazine—RYR2—Transmembrane transport of small molecules—SLC5A5—breast cancer	0.000215	0.00404	CbGpPWpGaD
Hydralazine—CYP3A4—Fatty Acid Omega Oxidation—CYP2D6—breast cancer	0.000215	0.00403	CbGpPWpGaD
Hydralazine—RYR2—SIDS Susceptibility Pathways—VEGFA—breast cancer	0.000209	0.00393	CbGpPWpGaD
Hydralazine—RYR2—Transmembrane transport of small molecules—SLC2A1—breast cancer	0.000208	0.0039	CbGpPWpGaD
Hydralazine—RYR2—Transmembrane transport of small molecules—NCOA1—breast cancer	0.00019	0.00357	CbGpPWpGaD
Hydralazine—RYR2—Transmembrane transport of small molecules—PLG—breast cancer	0.000185	0.00348	CbGpPWpGaD
Hydralazine—CYP3A4—Constitutive Androstane Receptor Pathway—GSTA2—breast cancer	0.000182	0.00341	CbGpPWpGaD
Hydralazine—CYP3A4—Xenobiotics—CYP2D6—breast cancer	0.00018	0.00337	CbGpPWpGaD
Hydralazine—RYR2—SIDS Susceptibility Pathways—TNF—breast cancer	0.000179	0.00337	CbGpPWpGaD
Hydralazine—CYP3A4—Constitutive Androstane Receptor Pathway—SULT1A1—breast cancer	0.000179	0.00337	CbGpPWpGaD
Hydralazine—CYP3A4—Estrogen metabolism—NQO1—breast cancer	0.000177	0.00332	CbGpPWpGaD
Hydralazine—CYP3A4—Tamoxifen metabolism—CYP2D6—breast cancer	0.000173	0.00324	CbGpPWpGaD
Hydralazine—CYP3A4—Tryptophan metabolism—ALDH1A1—breast cancer	0.000171	0.00321	CbGpPWpGaD
Hydralazine—RYR2—Transmembrane transport of small molecules—HMOX1—breast cancer	0.000171	0.00321	CbGpPWpGaD
Hydralazine—CYP3A4—Estrogen metabolism—CYP1B1—breast cancer	0.00017	0.00318	CbGpPWpGaD
Hydralazine—RYR2—Transmembrane transport of small molecules—ABCB1—breast cancer	0.000164	0.00308	CbGpPWpGaD
Hydralazine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—RARB—breast cancer	0.000151	0.00283	CbGpPWpGaD
Hydralazine—CYP3A4—Tamoxifen metabolism—CYP1B1—breast cancer	0.00015	0.00281	CbGpPWpGaD
Hydralazine—CYP3A4—Estrogen metabolism—COMT—breast cancer	0.000148	0.00278	CbGpPWpGaD
Hydralazine—CYP3A4—Drug Induction of Bile Acid Pathway—ABCB1—breast cancer	0.000146	0.00274	CbGpPWpGaD
Hydralazine—CYP3A4—Drug Induction of Bile Acid Pathway—VDR—breast cancer	0.000146	0.00274	CbGpPWpGaD
Hydralazine—RYR2—Myometrial Relaxation and Contraction Pathways—IL6—breast cancer	0.000146	0.00273	CbGpPWpGaD
Hydralazine—RYR2—SIDS Susceptibility Pathways—IL6—breast cancer	0.000145	0.00272	CbGpPWpGaD
Hydralazine—CYP3A4—Fatty Acid Omega Oxidation—CYP1A1—breast cancer	0.000141	0.00265	CbGpPWpGaD
Hydralazine—CYP3A4—Estrogen metabolism—GSTM1—breast cancer	0.000136	0.00254	CbGpPWpGaD
Hydralazine—CYP3A4—Estrogen metabolism—CYP1A1—breast cancer	0.000129	0.00241	CbGpPWpGaD
Hydralazine—CYP3A4—Irinotecan Pathway—APC—breast cancer	0.000123	0.00231	CbGpPWpGaD
Hydralazine—CYP3A4—Constitutive Androstane Receptor Pathway—NCOA2—breast cancer	0.000121	0.00227	CbGpPWpGaD
Hydralazine—CYP3A4—Xenobiotics—CYP1A1—breast cancer	0.000118	0.00222	CbGpPWpGaD
Hydralazine—CYP3A4—Tamoxifen metabolism—CYP1A1—breast cancer	0.000114	0.00213	CbGpPWpGaD
Hydralazine—CYP3A4—Phase 1 - Functionalization of compounds—ALDH1A1—breast cancer	0.000112	0.0021	CbGpPWpGaD
Hydralazine—Rash—Vinorelbine—breast cancer	0.000108	0.000473	CcSEcCtD
Hydralazine—Dermatitis—Vinorelbine—breast cancer	0.000108	0.000473	CcSEcCtD
Hydralazine—Hypotension—Paclitaxel—breast cancer	0.000107	0.000471	CcSEcCtD
Hydralazine—Ill-defined disorder—Capecitabine—breast cancer	0.000107	0.000471	CcSEcCtD
Hydralazine—Urticaria—Fluorouracil—breast cancer	0.000107	0.000471	CcSEcCtD
Hydralazine—Headache—Vinorelbine—breast cancer	0.000107	0.00047	CcSEcCtD
Hydralazine—Conjunctivitis—Methotrexate—breast cancer	0.000107	0.00047	CcSEcCtD
Hydralazine—Leukopenia—Docetaxel—breast cancer	0.000107	0.000469	CcSEcCtD
Hydralazine—Anaemia—Capecitabine—breast cancer	0.000107	0.000469	CcSEcCtD
Hydralazine—Body temperature increased—Fluorouracil—breast cancer	0.000107	0.000468	CcSEcCtD
Hydralazine—Eosinophilia—Doxorubicin—breast cancer	0.000106	0.000465	CcSEcCtD
Hydralazine—Palpitations—Docetaxel—breast cancer	0.000105	0.000463	CcSEcCtD
Hydralazine—CYP3A4—Constitutive Androstane Receptor Pathway—HSP90AA1—breast cancer	0.000105	0.00197	CbGpPWpGaD
Hydralazine—Haematuria—Methotrexate—breast cancer	0.000105	0.000461	CcSEcCtD
Hydralazine—Musculoskeletal discomfort—Paclitaxel—breast cancer	0.000105	0.00046	CcSEcCtD
Hydralazine—Weight decreased—Epirubicin—breast cancer	0.000105	0.000459	CcSEcCtD
Hydralazine—Malaise—Capecitabine—breast cancer	0.000104	0.000457	CcSEcCtD
Hydralazine—Angina pectoris—Doxorubicin—breast cancer	0.000104	0.000457	CcSEcCtD
Hydralazine—Hypersensitivity—Irinotecan—breast cancer	0.000104	0.000456	CcSEcCtD
Hydralazine—Hypersensitivity—Mitoxantrone—breast cancer	0.000104	0.000456	CcSEcCtD
Hydralazine—Vomiting—Thiotepa—breast cancer	0.000104	0.000455	CcSEcCtD
Hydralazine—Leukopenia—Capecitabine—breast cancer	0.000103	0.000454	CcSEcCtD
Hydralazine—Paraesthesia—Paclitaxel—breast cancer	0.000103	0.000453	CcSEcCtD
Hydralazine—Rash—Thiotepa—breast cancer	0.000103	0.000452	CcSEcCtD
Hydralazine—Dermatitis—Thiotepa—breast cancer	0.000103	0.000451	CcSEcCtD
Hydralazine—Agranulocytosis—Methotrexate—breast cancer	0.000103	0.000451	CcSEcCtD
Hydralazine—RYR2—Transmembrane transport of small molecules—ALB—breast cancer	0.000103	0.00193	CbGpPWpGaD
Hydralazine—Dyspnoea—Paclitaxel—breast cancer	0.000102	0.00045	CcSEcCtD
Hydralazine—Headache—Thiotepa—breast cancer	0.000102	0.000449	CcSEcCtD
Hydralazine—Palpitations—Capecitabine—breast cancer	0.000102	0.000448	CcSEcCtD
Hydralazine—CYP3A4—Constitutive Androstane Receptor Pathway—NCOA1—breast cancer	0.000102	0.00192	CbGpPWpGaD
Hydralazine—Arthralgia—Docetaxel—breast cancer	0.000102	0.000446	CcSEcCtD
Hydralazine—Myalgia—Docetaxel—breast cancer	0.000102	0.000446	CcSEcCtD
Hydralazine—Pancytopenia—Doxorubicin—breast cancer	0.000102	0.000446	CcSEcCtD
Hydralazine—Nausea—Vinorelbine—breast cancer	0.000101	0.000446	CcSEcCtD
Hydralazine—Dyspepsia—Paclitaxel—breast cancer	0.000101	0.000444	CcSEcCtD
Hydralazine—Neuropathy peripheral—Epirubicin—breast cancer	0.000101	0.000443	CcSEcCtD
Hydralazine—Jaundice—Epirubicin—breast cancer	0.0001	0.000441	CcSEcCtD
Hydralazine—Conjunctivitis—Epirubicin—breast cancer	0.0001	0.00044	CcSEcCtD
Hydralazine—Dysuria—Doxorubicin—breast cancer	0.0001	0.000439	CcSEcCtD
Hydralazine—Neutropenia—Doxorubicin—breast cancer	0.0001	0.000439	CcSEcCtD
Hydralazine—Decreased appetite—Paclitaxel—breast cancer	9.99e-05	0.000439	CcSEcCtD
Hydralazine—Hypersensitivity—Fluorouracil—breast cancer	9.94e-05	0.000437	CcSEcCtD
Hydralazine—Gastrointestinal disorder—Paclitaxel—breast cancer	9.92e-05	0.000436	CcSEcCtD
Hydralazine—Hepatitis—Methotrexate—breast cancer	9.88e-05	0.000434	CcSEcCtD
Hydralazine—Arthralgia—Capecitabine—breast cancer	9.84e-05	0.000432	CcSEcCtD
Hydralazine—Myalgia—Capecitabine—breast cancer	9.84e-05	0.000432	CcSEcCtD
Hydralazine—Constipation—Paclitaxel—breast cancer	9.83e-05	0.000431	CcSEcCtD
Hydralazine—Haematuria—Epirubicin—breast cancer	9.82e-05	0.000431	CcSEcCtD
Hydralazine—Anxiety—Capecitabine—breast cancer	9.8e-05	0.00043	CcSEcCtD
Hydralazine—Oedema—Docetaxel—breast cancer	9.74e-05	0.000428	CcSEcCtD
Hydralazine—Discomfort—Capecitabine—breast cancer	9.72e-05	0.000427	CcSEcCtD
Hydralazine—Pruritus—Gemcitabine—breast cancer	9.71e-05	0.000426	CcSEcCtD
Hydralazine—Nausea—Thiotepa—breast cancer	9.69e-05	0.000426	CcSEcCtD
Hydralazine—Weight decreased—Doxorubicin—breast cancer	9.67e-05	0.000425	CcSEcCtD
Hydralazine—Diarrhoea—Mitoxantrone—breast cancer	9.64e-05	0.000423	CcSEcCtD
Hydralazine—Diarrhoea—Irinotecan—breast cancer	9.64e-05	0.000423	CcSEcCtD
Hydralazine—Agranulocytosis—Epirubicin—breast cancer	9.61e-05	0.000422	CcSEcCtD
Hydralazine—Pruritus—Fluorouracil—breast cancer	9.55e-05	0.000419	CcSEcCtD
Hydralazine—Thrombocytopenia—Docetaxel—breast cancer	9.54e-05	0.000419	CcSEcCtD
Hydralazine—Tachycardia—Docetaxel—breast cancer	9.51e-05	0.000417	CcSEcCtD
Hydralazine—Feeling abnormal—Paclitaxel—breast cancer	9.47e-05	0.000416	CcSEcCtD
Hydralazine—Oedema—Capecitabine—breast cancer	9.43e-05	0.000414	CcSEcCtD
Hydralazine—Diarrhoea—Gemcitabine—breast cancer	9.39e-05	0.000412	CcSEcCtD
Hydralazine—Neuropathy peripheral—Doxorubicin—breast cancer	9.34e-05	0.00041	CcSEcCtD
Hydralazine—Dizziness—Irinotecan—breast cancer	9.32e-05	0.000409	CcSEcCtD
Hydralazine—Jaundice—Doxorubicin—breast cancer	9.29e-05	0.000408	CcSEcCtD
Hydralazine—Anorexia—Docetaxel—breast cancer	9.28e-05	0.000408	CcSEcCtD
Hydralazine—RYR2—Transmembrane transport of small molecules—RAF1—breast cancer	9.28e-05	0.00174	CbGpPWpGaD
Hydralazine—Conjunctivitis—Doxorubicin—breast cancer	9.26e-05	0.000407	CcSEcCtD
Hydralazine—Hepatitis—Epirubicin—breast cancer	9.25e-05	0.000406	CcSEcCtD
Hydralazine—Diarrhoea—Fluorouracil—breast cancer	9.23e-05	0.000405	CcSEcCtD
Hydralazine—Thrombocytopenia—Capecitabine—breast cancer	9.23e-05	0.000405	CcSEcCtD
Hydralazine—Tachycardia—Capecitabine—breast cancer	9.2e-05	0.000404	CcSEcCtD
Hydralazine—Hypoaesthesia—Epirubicin—breast cancer	9.2e-05	0.000404	CcSEcCtD
Hydralazine—Urticaria—Paclitaxel—breast cancer	9.13e-05	0.000401	CcSEcCtD
Hydralazine—Hypotension—Docetaxel—breast cancer	9.1e-05	0.0004	CcSEcCtD
Hydralazine—Haematuria—Doxorubicin—breast cancer	9.09e-05	0.000399	CcSEcCtD
Hydralazine—Body temperature increased—Paclitaxel—breast cancer	9.08e-05	0.000399	CcSEcCtD
Hydralazine—Anorexia—Capecitabine—breast cancer	8.99e-05	0.000395	CcSEcCtD
Hydralazine—Vomiting—Irinotecan—breast cancer	8.96e-05	0.000393	CcSEcCtD
Hydralazine—Vomiting—Mitoxantrone—breast cancer	8.96e-05	0.000393	CcSEcCtD
Hydralazine—Dizziness—Fluorouracil—breast cancer	8.92e-05	0.000392	CcSEcCtD
Hydralazine—Agranulocytosis—Doxorubicin—breast cancer	8.89e-05	0.000391	CcSEcCtD
Hydralazine—Rash—Irinotecan—breast cancer	8.88e-05	0.00039	CcSEcCtD
Hydralazine—Rash—Mitoxantrone—breast cancer	8.88e-05	0.00039	CcSEcCtD
Hydralazine—Dermatitis—Irinotecan—breast cancer	8.88e-05	0.00039	CcSEcCtD
Hydralazine—Dermatitis—Mitoxantrone—breast cancer	8.88e-05	0.00039	CcSEcCtD
Hydralazine—Musculoskeletal discomfort—Docetaxel—breast cancer	8.87e-05	0.00039	CcSEcCtD
Hydralazine—Chills—Methotrexate—breast cancer	8.87e-05	0.000389	CcSEcCtD
Hydralazine—Headache—Mitoxantrone—breast cancer	8.83e-05	0.000388	CcSEcCtD
Hydralazine—Headache—Irinotecan—breast cancer	8.83e-05	0.000388	CcSEcCtD
Hydralazine—CYP3A4—Constitutive Androstane Receptor Pathway—ABCB1—breast cancer	8.81e-05	0.00165	CbGpPWpGaD
Hydralazine—Hypotension—Capecitabine—breast cancer	8.81e-05	0.000387	CcSEcCtD
Hydralazine—Paraesthesia—Docetaxel—breast cancer	8.75e-05	0.000384	CcSEcCtD
Hydralazine—Vomiting—Gemcitabine—breast cancer	8.73e-05	0.000383	CcSEcCtD
Hydralazine—Dyspnoea—Docetaxel—breast cancer	8.68e-05	0.000381	CcSEcCtD
Hydralazine—Rash—Gemcitabine—breast cancer	8.65e-05	0.00038	CcSEcCtD
Hydralazine—Dermatitis—Gemcitabine—breast cancer	8.65e-05	0.00038	CcSEcCtD
Hydralazine—Headache—Gemcitabine—breast cancer	8.6e-05	0.000378	CcSEcCtD
Hydralazine—Musculoskeletal discomfort—Capecitabine—breast cancer	8.59e-05	0.000377	CcSEcCtD
Hydralazine—Flushing—Epirubicin—breast cancer	8.58e-05	0.000377	CcSEcCtD
Hydralazine—Vomiting—Fluorouracil—breast cancer	8.58e-05	0.000377	CcSEcCtD
Hydralazine—Dyspepsia—Docetaxel—breast cancer	8.57e-05	0.000376	CcSEcCtD
Hydralazine—CYP3A4—Metapathway biotransformation—CHST9—breast cancer	8.57e-05	0.00161	CbGpPWpGaD
Hydralazine—Hepatitis—Doxorubicin—breast cancer	8.56e-05	0.000376	CcSEcCtD
Hydralazine—Hypoaesthesia—Doxorubicin—breast cancer	8.51e-05	0.000374	CcSEcCtD
Hydralazine—Rash—Fluorouracil—breast cancer	8.51e-05	0.000374	CcSEcCtD
Hydralazine—Dermatitis—Fluorouracil—breast cancer	8.5e-05	0.000373	CcSEcCtD
Hydralazine—Paraesthesia—Capecitabine—breast cancer	8.47e-05	0.000372	CcSEcCtD
Hydralazine—Decreased appetite—Docetaxel—breast cancer	8.47e-05	0.000372	CcSEcCtD
Hydralazine—Hypersensitivity—Paclitaxel—breast cancer	8.47e-05	0.000372	CcSEcCtD
Hydralazine—Headache—Fluorouracil—breast cancer	8.45e-05	0.000371	CcSEcCtD
Hydralazine—Gastrointestinal disorder—Docetaxel—breast cancer	8.41e-05	0.000369	CcSEcCtD
Hydralazine—Dyspnoea—Capecitabine—breast cancer	8.41e-05	0.000369	CcSEcCtD
Hydralazine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—breast cancer	8.4e-05	0.00158	CbGpPWpGaD
Hydralazine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—breast cancer	8.38e-05	0.00157	CbGpPWpGaD
Hydralazine—Nausea—Mitoxantrone—breast cancer	8.37e-05	0.000367	CcSEcCtD
Hydralazine—Nausea—Irinotecan—breast cancer	8.37e-05	0.000367	CcSEcCtD
Hydralazine—Constipation—Docetaxel—breast cancer	8.33e-05	0.000366	CcSEcCtD
Hydralazine—Dyspepsia—Capecitabine—breast cancer	8.3e-05	0.000364	CcSEcCtD
Hydralazine—Chills—Epirubicin—breast cancer	8.3e-05	0.000364	CcSEcCtD
Hydralazine—Decreased appetite—Capecitabine—breast cancer	8.2e-05	0.00036	CcSEcCtD
Hydralazine—Nausea—Gemcitabine—breast cancer	8.15e-05	0.000358	CcSEcCtD
Hydralazine—Gastrointestinal disorder—Capecitabine—breast cancer	8.14e-05	0.000357	CcSEcCtD
Hydralazine—Pruritus—Paclitaxel—breast cancer	8.13e-05	0.000357	CcSEcCtD
Hydralazine—Constipation—Capecitabine—breast cancer	8.06e-05	0.000354	CcSEcCtD
Hydralazine—Feeling abnormal—Docetaxel—breast cancer	8.03e-05	0.000352	CcSEcCtD
Hydralazine—Nausea—Fluorouracil—breast cancer	8.02e-05	0.000352	CcSEcCtD
Hydralazine—CYP3A4—Tryptophan metabolism—CYP1B1—breast cancer	8.01e-05	0.0015	CbGpPWpGaD
Hydralazine—Ill-defined disorder—Methotrexate—breast cancer	7.98e-05	0.00035	CcSEcCtD
Hydralazine—Anaemia—Methotrexate—breast cancer	7.95e-05	0.000349	CcSEcCtD
Hydralazine—Flushing—Doxorubicin—breast cancer	7.94e-05	0.000349	CcSEcCtD
Hydralazine—Diarrhoea—Paclitaxel—breast cancer	7.86e-05	0.000345	CcSEcCtD
Hydralazine—Feeling abnormal—Capecitabine—breast cancer	7.77e-05	0.000341	CcSEcCtD
Hydralazine—Malaise—Methotrexate—breast cancer	7.76e-05	0.000341	CcSEcCtD
Hydralazine—Muscle spasms—Epirubicin—breast cancer	7.74e-05	0.00034	CcSEcCtD
Hydralazine—Body temperature increased—Docetaxel—breast cancer	7.7e-05	0.000338	CcSEcCtD
Hydralazine—Leukopenia—Methotrexate—breast cancer	7.7e-05	0.000338	CcSEcCtD
Hydralazine—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP17A1—breast cancer	7.69e-05	0.00144	CbGpPWpGaD
Hydralazine—Chills—Doxorubicin—breast cancer	7.68e-05	0.000337	CcSEcCtD
Hydralazine—Dizziness—Paclitaxel—breast cancer	7.6e-05	0.000334	CcSEcCtD
Hydralazine—CYP3A4—Oxidation by Cytochrome P450—CYP17A1—breast cancer	7.59e-05	0.00142	CbGpPWpGaD
Hydralazine—CYP3A4—Tryptophan metabolism—CYP19A1—breast cancer	7.53e-05	0.00141	CbGpPWpGaD
Hydralazine—Urticaria—Capecitabine—breast cancer	7.49e-05	0.000329	CcSEcCtD
Hydralazine—Ill-defined disorder—Epirubicin—breast cancer	7.47e-05	0.000328	CcSEcCtD
Hydralazine—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2D6—breast cancer	7.46e-05	0.0014	CbGpPWpGaD
Hydralazine—Body temperature increased—Capecitabine—breast cancer	7.45e-05	0.000327	CcSEcCtD
Hydralazine—Anaemia—Epirubicin—breast cancer	7.44e-05	0.000327	CcSEcCtD
Hydralazine—Agitation—Epirubicin—breast cancer	7.4e-05	0.000325	CcSEcCtD
Hydralazine—CYP3A4—Oxidation by Cytochrome P450—CYP2D6—breast cancer	7.37e-05	0.00138	CbGpPWpGaD
Hydralazine—CYP3A4—Cytochrome P450 - arranged by substrate type—NCOA2—breast cancer	7.33e-05	0.00138	CbGpPWpGaD
Hydralazine—Myalgia—Methotrexate—breast cancer	7.32e-05	0.000322	CcSEcCtD
Hydralazine—Arthralgia—Methotrexate—breast cancer	7.32e-05	0.000322	CcSEcCtD
Hydralazine—Vomiting—Paclitaxel—breast cancer	7.31e-05	0.000321	CcSEcCtD
Hydralazine—Malaise—Epirubicin—breast cancer	7.26e-05	0.000319	CcSEcCtD
Hydralazine—Rash—Paclitaxel—breast cancer	7.25e-05	0.000318	CcSEcCtD
Hydralazine—Dermatitis—Paclitaxel—breast cancer	7.24e-05	0.000318	CcSEcCtD
Hydralazine—Discomfort—Methotrexate—breast cancer	7.24e-05	0.000318	CcSEcCtD
Hydralazine—Leukopenia—Epirubicin—breast cancer	7.21e-05	0.000316	CcSEcCtD
Hydralazine—Headache—Paclitaxel—breast cancer	7.2e-05	0.000316	CcSEcCtD
Hydralazine—Hypersensitivity—Docetaxel—breast cancer	7.18e-05	0.000315	CcSEcCtD
Hydralazine—Muscle spasms—Doxorubicin—breast cancer	7.16e-05	0.000314	CcSEcCtD
Hydralazine—Palpitations—Epirubicin—breast cancer	7.11e-05	0.000312	CcSEcCtD
Hydralazine—Hypersensitivity—Capecitabine—breast cancer	6.95e-05	0.000305	CcSEcCtD
Hydralazine—Ill-defined disorder—Doxorubicin—breast cancer	6.91e-05	0.000303	CcSEcCtD
Hydralazine—Pruritus—Docetaxel—breast cancer	6.89e-05	0.000303	CcSEcCtD
Hydralazine—Anaemia—Doxorubicin—breast cancer	6.88e-05	0.000302	CcSEcCtD
Hydralazine—Thrombocytopenia—Methotrexate—breast cancer	6.87e-05	0.000302	CcSEcCtD
Hydralazine—Arthralgia—Epirubicin—breast cancer	6.85e-05	0.000301	CcSEcCtD
Hydralazine—Myalgia—Epirubicin—breast cancer	6.85e-05	0.000301	CcSEcCtD
Hydralazine—Agitation—Doxorubicin—breast cancer	6.84e-05	0.000301	CcSEcCtD
Hydralazine—Anxiety—Epirubicin—breast cancer	6.83e-05	0.0003	CcSEcCtD
Hydralazine—Nausea—Paclitaxel—breast cancer	6.83e-05	0.0003	CcSEcCtD
Hydralazine—Discomfort—Epirubicin—breast cancer	6.77e-05	0.000297	CcSEcCtD
Hydralazine—Malaise—Doxorubicin—breast cancer	6.72e-05	0.000295	CcSEcCtD
Hydralazine—Anorexia—Methotrexate—breast cancer	6.69e-05	0.000294	CcSEcCtD
Hydralazine—Pruritus—Capecitabine—breast cancer	6.67e-05	0.000293	CcSEcCtD
Hydralazine—Leukopenia—Doxorubicin—breast cancer	6.67e-05	0.000293	CcSEcCtD
Hydralazine—Diarrhoea—Docetaxel—breast cancer	6.66e-05	0.000293	CcSEcCtD
Hydralazine—Palpitations—Doxorubicin—breast cancer	6.58e-05	0.000289	CcSEcCtD
Hydralazine—Oedema—Epirubicin—breast cancer	6.57e-05	0.000288	CcSEcCtD
Hydralazine—Hypotension—Methotrexate—breast cancer	6.56e-05	0.000288	CcSEcCtD
Hydralazine—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1B1—breast cancer	6.47e-05	0.00121	CbGpPWpGaD
Hydralazine—Diarrhoea—Capecitabine—breast cancer	6.45e-05	0.000283	CcSEcCtD
Hydralazine—Dizziness—Docetaxel—breast cancer	6.44e-05	0.000283	CcSEcCtD
Hydralazine—Thrombocytopenia—Epirubicin—breast cancer	6.43e-05	0.000282	CcSEcCtD
Hydralazine—Tachycardia—Epirubicin—breast cancer	6.41e-05	0.000282	CcSEcCtD
Hydralazine—Musculoskeletal discomfort—Methotrexate—breast cancer	6.4e-05	0.000281	CcSEcCtD
Hydralazine—CYP3A4—Oxidation by Cytochrome P450—CYP1B1—breast cancer	6.39e-05	0.0012	CbGpPWpGaD
Hydralazine—Arthralgia—Doxorubicin—breast cancer	6.34e-05	0.000278	CcSEcCtD
Hydralazine—Myalgia—Doxorubicin—breast cancer	6.34e-05	0.000278	CcSEcCtD
Hydralazine—Anxiety—Doxorubicin—breast cancer	6.32e-05	0.000277	CcSEcCtD
Hydralazine—Paraesthesia—Methotrexate—breast cancer	6.3e-05	0.000277	CcSEcCtD
Hydralazine—Discomfort—Doxorubicin—breast cancer	6.26e-05	0.000275	CcSEcCtD
Hydralazine—Anorexia—Epirubicin—breast cancer	6.26e-05	0.000275	CcSEcCtD
Hydralazine—Dyspnoea—Methotrexate—breast cancer	6.26e-05	0.000275	CcSEcCtD
Hydralazine—Dizziness—Capecitabine—breast cancer	6.24e-05	0.000274	CcSEcCtD
Hydralazine—CYP3A4—Phase 1 - Functionalization of compounds—CYP17A1—breast cancer	6.23e-05	0.00117	CbGpPWpGaD
Hydralazine—Vomiting—Docetaxel—breast cancer	6.19e-05	0.000272	CcSEcCtD
Hydralazine—Dyspepsia—Methotrexate—breast cancer	6.18e-05	0.000271	CcSEcCtD
Hydralazine—CYP3A4—Cytochrome P450 - arranged by substrate type—NCOA1—breast cancer	6.17e-05	0.00116	CbGpPWpGaD
Hydralazine—CYP3A4—Phase 1 - Functionalization of compounds—PTGS1—breast cancer	6.17e-05	0.00116	CbGpPWpGaD
Hydralazine—Rash—Docetaxel—breast cancer	6.14e-05	0.00027	CcSEcCtD
Hydralazine—Hypotension—Epirubicin—breast cancer	6.14e-05	0.00027	CcSEcCtD
Hydralazine—Dermatitis—Docetaxel—breast cancer	6.14e-05	0.000269	CcSEcCtD
Hydralazine—Decreased appetite—Methotrexate—breast cancer	6.1e-05	0.000268	CcSEcCtD
Hydralazine—Headache—Docetaxel—breast cancer	6.1e-05	0.000268	CcSEcCtD
Hydralazine—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP19A1—breast cancer	6.09e-05	0.00114	CbGpPWpGaD
Hydralazine—Oedema—Doxorubicin—breast cancer	6.08e-05	0.000267	CcSEcCtD
Hydralazine—CYP3A4—Tryptophan metabolism—CYP1A1—breast cancer	6.07e-05	0.00114	CbGpPWpGaD
Hydralazine—Gastrointestinal disorder—Methotrexate—breast cancer	6.06e-05	0.000266	CcSEcCtD
Hydralazine—CYP3A4—Phase 1 - Functionalization of compounds—CYP2D6—breast cancer	6.05e-05	0.00114	CbGpPWpGaD
Hydralazine—CYP3A4—Oxidation by Cytochrome P450—CYP19A1—breast cancer	6.01e-05	0.00113	CbGpPWpGaD
Hydralazine—Vomiting—Capecitabine—breast cancer	6e-05	0.000263	CcSEcCtD
Hydralazine—Musculoskeletal discomfort—Epirubicin—breast cancer	5.99e-05	0.000263	CcSEcCtD
Hydralazine—CYP3A4—Biological oxidations—ALDH1A1—breast cancer	5.95e-05	0.00112	CbGpPWpGaD
Hydralazine—Thrombocytopenia—Doxorubicin—breast cancer	5.95e-05	0.000261	CcSEcCtD
Hydralazine—Rash—Capecitabine—breast cancer	5.95e-05	0.000261	CcSEcCtD
Hydralazine—Dermatitis—Capecitabine—breast cancer	5.94e-05	0.000261	CcSEcCtD
Hydralazine—CYP3A4—Phase 1 - Functionalization of compounds—NCOA2—breast cancer	5.94e-05	0.00111	CbGpPWpGaD
Hydralazine—Tachycardia—Doxorubicin—breast cancer	5.93e-05	0.00026	CcSEcCtD
Hydralazine—Headache—Capecitabine—breast cancer	5.91e-05	0.000259	CcSEcCtD
Hydralazine—Paraesthesia—Epirubicin—breast cancer	5.9e-05	0.000259	CcSEcCtD
Hydralazine—Dyspnoea—Epirubicin—breast cancer	5.86e-05	0.000257	CcSEcCtD
Hydralazine—Anorexia—Doxorubicin—breast cancer	5.79e-05	0.000254	CcSEcCtD
Hydralazine—Nausea—Docetaxel—breast cancer	5.79e-05	0.000254	CcSEcCtD
Hydralazine—Feeling abnormal—Methotrexate—breast cancer	5.78e-05	0.000254	CcSEcCtD
Hydralazine—Dyspepsia—Epirubicin—breast cancer	5.78e-05	0.000254	CcSEcCtD
Hydralazine—Decreased appetite—Epirubicin—breast cancer	5.71e-05	0.000251	CcSEcCtD
Hydralazine—Hypotension—Doxorubicin—breast cancer	5.68e-05	0.000249	CcSEcCtD
Hydralazine—Gastrointestinal disorder—Epirubicin—breast cancer	5.67e-05	0.000249	CcSEcCtD
Hydralazine—Constipation—Epirubicin—breast cancer	5.62e-05	0.000247	CcSEcCtD
Hydralazine—Nausea—Capecitabine—breast cancer	5.6e-05	0.000246	CcSEcCtD
Hydralazine—Urticaria—Methotrexate—breast cancer	5.58e-05	0.000245	CcSEcCtD
Hydralazine—Body temperature increased—Methotrexate—breast cancer	5.55e-05	0.000244	CcSEcCtD
Hydralazine—Musculoskeletal discomfort—Doxorubicin—breast cancer	5.54e-05	0.000243	CcSEcCtD
Hydralazine—Paraesthesia—Doxorubicin—breast cancer	5.46e-05	0.00024	CcSEcCtD
Hydralazine—Dyspnoea—Doxorubicin—breast cancer	5.42e-05	0.000238	CcSEcCtD
Hydralazine—Feeling abnormal—Epirubicin—breast cancer	5.41e-05	0.000238	CcSEcCtD
Hydralazine—Dyspepsia—Doxorubicin—breast cancer	5.35e-05	0.000235	CcSEcCtD
Hydralazine—CYP3A4—Biological oxidations—GSTA3—breast cancer	5.31e-05	0.000996	CbGpPWpGaD
Hydralazine—Decreased appetite—Doxorubicin—breast cancer	5.28e-05	0.000232	CcSEcCtD
Hydralazine—Gastrointestinal disorder—Doxorubicin—breast cancer	5.25e-05	0.00023	CcSEcCtD
Hydralazine—CYP3A4—Phase 1 - Functionalization of compounds—CYP1B1—breast cancer	5.25e-05	0.000985	CbGpPWpGaD
Hydralazine—CYP3A4—Metapathway biotransformation—GSTA3—breast cancer	5.23e-05	0.000982	CbGpPWpGaD
Hydralazine—Urticaria—Epirubicin—breast cancer	5.22e-05	0.000229	CcSEcCtD
Hydralazine—Constipation—Doxorubicin—breast cancer	5.2e-05	0.000228	CcSEcCtD
Hydralazine—Body temperature increased—Epirubicin—breast cancer	5.19e-05	0.000228	CcSEcCtD
Hydralazine—Hypersensitivity—Methotrexate—breast cancer	5.17e-05	0.000227	CcSEcCtD
Hydralazine—Feeling abnormal—Doxorubicin—breast cancer	5.01e-05	0.00022	CcSEcCtD
Hydralazine—CYP3A4—Phase 1 - Functionalization of compounds—NCOA1—breast cancer	5.01e-05	0.000939	CbGpPWpGaD
Hydralazine—Pruritus—Methotrexate—breast cancer	4.97e-05	0.000218	CcSEcCtD
Hydralazine—CYP3A4—Phase 1 - Functionalization of compounds—CYP19A1—breast cancer	4.93e-05	0.000926	CbGpPWpGaD
Hydralazine—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1A1—breast cancer	4.91e-05	0.00092	CbGpPWpGaD
Hydralazine—CYP3A4—Biological oxidations—GSTA4—breast cancer	4.85e-05	0.000911	CbGpPWpGaD
Hydralazine—CYP3A4—Oxidation by Cytochrome P450—CYP1A1—breast cancer	4.84e-05	0.000908	CbGpPWpGaD
Hydralazine—Hypersensitivity—Epirubicin—breast cancer	4.84e-05	0.000213	CcSEcCtD
Hydralazine—Urticaria—Doxorubicin—breast cancer	4.83e-05	0.000212	CcSEcCtD
Hydralazine—Body temperature increased—Doxorubicin—breast cancer	4.81e-05	0.000211	CcSEcCtD
Hydralazine—Diarrhoea—Methotrexate—breast cancer	4.8e-05	0.000211	CcSEcCtD
Hydralazine—CYP3A4—Metapathway biotransformation—GSTA4—breast cancer	4.79e-05	0.000898	CbGpPWpGaD
Hydralazine—CYP3A4—Biological oxidations—GSTA2—breast cancer	4.73e-05	0.000887	CbGpPWpGaD
Hydralazine—CYP3A4—Biological oxidations—SULT1A1—breast cancer	4.67e-05	0.000877	CbGpPWpGaD
Hydralazine—CYP3A4—Metapathway biotransformation—GPX2—breast cancer	4.66e-05	0.000875	CbGpPWpGaD
Hydralazine—Pruritus—Epirubicin—breast cancer	4.65e-05	0.000204	CcSEcCtD
Hydralazine—Dizziness—Methotrexate—breast cancer	4.64e-05	0.000204	CcSEcCtD
Hydralazine—CYP3A4—Metapathway biotransformation—SULT1A1—breast cancer	4.61e-05	0.000865	CbGpPWpGaD
Hydralazine—CYP3A4—Metapathway biotransformation—GPX4—breast cancer	4.61e-05	0.000865	CbGpPWpGaD
Hydralazine—CYP3A4—Biological oxidations—GSTA1—breast cancer	4.56e-05	0.000856	CbGpPWpGaD
Hydralazine—CYP3A4—Biological oxidations—NAT2—breast cancer	4.51e-05	0.000847	CbGpPWpGaD
Hydralazine—Diarrhoea—Epirubicin—breast cancer	4.49e-05	0.000197	CcSEcCtD
Hydralazine—Hypersensitivity—Doxorubicin—breast cancer	4.48e-05	0.000197	CcSEcCtD
Hydralazine—Vomiting—Methotrexate—breast cancer	4.46e-05	0.000196	CcSEcCtD
Hydralazine—CYP3A4—Metapathway biotransformation—NAT2—breast cancer	4.45e-05	0.000835	CbGpPWpGaD
Hydralazine—Rash—Methotrexate—breast cancer	4.43e-05	0.000194	CcSEcCtD
Hydralazine—Dermatitis—Methotrexate—breast cancer	4.42e-05	0.000194	CcSEcCtD
Hydralazine—Headache—Methotrexate—breast cancer	4.4e-05	0.000193	CcSEcCtD
Hydralazine—Dizziness—Epirubicin—breast cancer	4.34e-05	0.000191	CcSEcCtD
Hydralazine—Pruritus—Doxorubicin—breast cancer	4.3e-05	0.000189	CcSEcCtD
Hydralazine—Vomiting—Epirubicin—breast cancer	4.18e-05	0.000183	CcSEcCtD
Hydralazine—Nausea—Methotrexate—breast cancer	4.17e-05	0.000183	CcSEcCtD
Hydralazine—Diarrhoea—Doxorubicin—breast cancer	4.16e-05	0.000183	CcSEcCtD
Hydralazine—Rash—Epirubicin—breast cancer	4.14e-05	0.000182	CcSEcCtD
Hydralazine—Dermatitis—Epirubicin—breast cancer	4.14e-05	0.000182	CcSEcCtD
Hydralazine—Headache—Epirubicin—breast cancer	4.12e-05	0.000181	CcSEcCtD
Hydralazine—Dizziness—Doxorubicin—breast cancer	4.02e-05	0.000176	CcSEcCtD
Hydralazine—CYP3A4—Phase 1 - Functionalization of compounds—CYP1A1—breast cancer	3.98e-05	0.000746	CbGpPWpGaD
Hydralazine—Nausea—Epirubicin—breast cancer	3.9e-05	0.000171	CcSEcCtD
Hydralazine—Vomiting—Doxorubicin—breast cancer	3.86e-05	0.00017	CcSEcCtD
Hydralazine—Rash—Doxorubicin—breast cancer	3.83e-05	0.000168	CcSEcCtD
Hydralazine—Dermatitis—Doxorubicin—breast cancer	3.83e-05	0.000168	CcSEcCtD
Hydralazine—Headache—Doxorubicin—breast cancer	3.81e-05	0.000167	CcSEcCtD
Hydralazine—CYP3A4—Tryptophan metabolism—MDM2—breast cancer	3.74e-05	0.000702	CbGpPWpGaD
Hydralazine—CYP3A4—Biological oxidations—MTR—breast cancer	3.68e-05	0.00069	CbGpPWpGaD
Hydralazine—Nausea—Doxorubicin—breast cancer	3.61e-05	0.000159	CcSEcCtD
Hydralazine—CYP3A4—Biological oxidations—HPGDS—breast cancer	3.61e-05	0.000677	CbGpPWpGaD
Hydralazine—CYP3A4—Biological oxidations—GSTT1—breast cancer	3.5e-05	0.000656	CbGpPWpGaD
Hydralazine—CYP3A4—Biological oxidations—CYP17A1—breast cancer	3.31e-05	0.000621	CbGpPWpGaD
Hydralazine—CYP3A4—Biological oxidations—PTGS1—breast cancer	3.28e-05	0.000615	CbGpPWpGaD
Hydralazine—CYP3A4—Metapathway biotransformation—CYP17A1—breast cancer	3.27e-05	0.000613	CbGpPWpGaD
Hydralazine—CYP3A4—Biological oxidations—CYP2D6—breast cancer	3.21e-05	0.000603	CbGpPWpGaD
Hydralazine—CYP3A4—Metapathway biotransformation—CYP2D6—breast cancer	3.17e-05	0.000595	CbGpPWpGaD
Hydralazine—CYP3A4—Biological oxidations—NCOA2—breast cancer	3.16e-05	0.000592	CbGpPWpGaD
Hydralazine—CYP3A4—Biological oxidations—CYP1B1—breast cancer	2.79e-05	0.000523	CbGpPWpGaD
Hydralazine—CYP3A4—Metapathway biotransformation—CYP1B1—breast cancer	2.75e-05	0.000516	CbGpPWpGaD
Hydralazine—CYP3A4—Biological oxidations—NCOA1—breast cancer	2.66e-05	0.000499	CbGpPWpGaD
Hydralazine—CYP3A4—Biological oxidations—CYP19A1—breast cancer	2.62e-05	0.000492	CbGpPWpGaD
Hydralazine—CYP3A4—Metapathway biotransformation—CYP19A1—breast cancer	2.58e-05	0.000485	CbGpPWpGaD
Hydralazine—CYP3A4—Biological oxidations—COMT—breast cancer	2.44e-05	0.000457	CbGpPWpGaD
Hydralazine—CYP3A4—Biological oxidations—GSTP1—breast cancer	2.42e-05	0.000455	CbGpPWpGaD
Hydralazine—CYP3A4—Metapathway biotransformation—COMT—breast cancer	2.4e-05	0.000451	CbGpPWpGaD
Hydralazine—CYP3A4—Metapathway biotransformation—GSTP1—breast cancer	2.39e-05	0.000449	CbGpPWpGaD
Hydralazine—CYP3A4—Biological oxidations—GSTM1—breast cancer	2.23e-05	0.000418	CbGpPWpGaD
Hydralazine—CYP3A4—Metapathway biotransformation—GSTM1—breast cancer	2.2e-05	0.000412	CbGpPWpGaD
Hydralazine—CYP3A4—Biological oxidations—CYP1A1—breast cancer	2.11e-05	0.000396	CbGpPWpGaD
Hydralazine—CYP3A4—Metapathway biotransformation—CYP1A1—breast cancer	2.08e-05	0.000391	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—SYNJ2—breast cancer	1.7e-05	0.000319	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—NDUFS3—breast cancer	1.58e-05	0.000296	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—CHST9—breast cancer	1.49e-05	0.000279	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—COX11—breast cancer	1.41e-05	0.000264	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—SHMT1—breast cancer	1.29e-05	0.000242	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—CDA—breast cancer	1.29e-05	0.000242	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—SLC2A5—breast cancer	1.24e-05	0.000233	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—SLCO1B1—breast cancer	1.24e-05	0.000233	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—APRT—breast cancer	1.2e-05	0.000225	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—ESRRA—breast cancer	1.13e-05	0.000211	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—ANGPTL4—breast cancer	1.13e-05	0.000211	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—HADHB—breast cancer	1.07e-05	0.0002	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—GPI—breast cancer	1.07e-05	0.0002	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—ALDH7A1—breast cancer	1.02e-05	0.000191	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—ALDH1A1—breast cancer	1.02e-05	0.000191	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—FHL2—breast cancer	9.76e-06	0.000183	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—NME1—breast cancer	9.76e-06	0.000183	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—ADSL—breast cancer	9.76e-06	0.000183	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—PHGDH—breast cancer	9.76e-06	0.000183	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—UMPS—breast cancer	9.76e-06	0.000183	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—BRIP1—breast cancer	9.57e-06	0.00018	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—LDHB—breast cancer	9.57e-06	0.00018	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—HPSE—breast cancer	9.57e-06	0.00018	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—GSTA3—breast cancer	9.07e-06	0.00017	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—HMMR—breast cancer	9.07e-06	0.00017	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—ABCC1—breast cancer	9.07e-06	0.00017	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—PPARGC1B—breast cancer	8.79e-06	0.000165	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—CA9—breast cancer	8.3e-06	0.000156	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—GSTA4—breast cancer	8.3e-06	0.000156	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—GPX2—breast cancer	8.09e-06	0.000152	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—GSTA2—breast cancer	8.09e-06	0.000152	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—GPX4—breast cancer	7.99e-06	0.00015	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—SULT1A1—breast cancer	7.99e-06	0.00015	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—GSTA1—breast cancer	7.8e-06	0.000146	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—IDH1—breast cancer	7.8e-06	0.000146	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—NAT2—breast cancer	7.72e-06	0.000145	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—MED12—breast cancer	6.77e-06	0.000127	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—DPYD—breast cancer	6.77e-06	0.000127	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—ALDOA—breast cancer	6.66e-06	0.000125	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—NCOA3—breast cancer	6.47e-06	0.000121	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—SLC2A2—breast cancer	6.42e-06	0.00012	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—MTR—breast cancer	6.29e-06	0.000118	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—CPT1A—breast cancer	6.29e-06	0.000118	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—ABCG2—breast cancer	6.29e-06	0.000118	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—HPGDS—breast cancer	6.17e-06	0.000116	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—HBA1—breast cancer	6.13e-06	0.000115	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—GSTT1—breast cancer	5.98e-06	0.000112	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—ACHE—breast cancer	5.98e-06	0.000112	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—CYP17A1—breast cancer	5.66e-06	0.000106	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—ENO1—breast cancer	5.61e-06	0.000105	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—PTGS1—breast cancer	5.61e-06	0.000105	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—CYP2D6—breast cancer	5.5e-06	0.000103	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—NCOA2—breast cancer	5.4e-06	0.000101	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—FASN—breast cancer	5.23e-06	9.82e-05	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—BCHE—breast cancer	5.21e-06	9.78e-05	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—SLC5A5—breast cancer	5.15e-06	9.66e-05	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—SLC2A1—breast cancer	4.97e-06	9.33e-05	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—NQO1—breast cancer	4.97e-06	9.33e-05	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—CYP1B1—breast cancer	4.77e-06	8.94e-05	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—HSP90AA1—breast cancer	4.67e-06	8.77e-05	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—NCOA1—breast cancer	4.55e-06	8.53e-05	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—STK11—breast cancer	4.48e-06	8.41e-05	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—CYP19A1—breast cancer	4.48e-06	8.41e-05	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—COMT—breast cancer	4.17e-06	7.82e-05	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—GSTP1—breast cancer	4.15e-06	7.78e-05	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—HMOX1—breast cancer	4.09e-06	7.67e-05	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—ITPR1—breast cancer	4.08e-06	7.66e-05	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—ABCB1—breast cancer	3.93e-06	7.37e-05	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—TYMS—breast cancer	3.85e-06	7.23e-05	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—NCOR1—breast cancer	3.81e-06	7.15e-05	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—PLA2G4A—breast cancer	3.81e-06	7.15e-05	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—GSTM1—breast cancer	3.81e-06	7.15e-05	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—GPX1—breast cancer	3.65e-06	6.85e-05	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—CYP1A1—breast cancer	3.61e-06	6.78e-05	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—ERCC2—breast cancer	3.58e-06	6.72e-05	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—MTHFR—breast cancer	3.37e-06	6.32e-05	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—CAV1—breast cancer	3.11e-06	5.83e-05	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—PIK3CG—breast cancer	2.83e-06	5.31e-05	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—PIK3CD—breast cancer	2.49e-06	4.67e-05	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—ALB—breast cancer	2.46e-06	4.61e-05	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—NOS3—breast cancer	2.35e-06	4.41e-05	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—PIK3CB—breast cancer	2.17e-06	4.07e-05	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—PTGS2—breast cancer	2.15e-06	4.03e-05	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—PTEN—breast cancer	1.87e-06	3.52e-05	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—PIK3CA—breast cancer	1.32e-06	2.48e-05	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—AKT1—breast cancer	1.08e-06	2.03e-05	CbGpPWpGaD
